Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit

Table 5 Summary of treatment-emergent adverse events by participant

Adverse Event (AE)	PF-03654764 + fexofenadine (N = 48)	PF-03654764 (N = 15)	Pseudoephedrine + fexofenadine (N = 61)	Placebo (n = 15)
All Causalities
Number of AEs	116	39	30	3
Participants with AEs	36 (75)	12 (80)	18 (29.5)	3 (20)
Participants with severe AEs	23 (49)	6 (40)	4 (6.6)	0
Participants discontinued due to AEs	2 (4.2)	1 (6.7)	0	0
Treatment-Related
Number of AEs	83	30	11	0
Participants with AEs	22 (45.8)	11 (73.3)	6 (9.8)	0
Participants with severe AEs	17 (35.4)	6 (40.0)	2 (3.3)	0
Participants discontinued due to AEs	2 (4.2)	0	0	0

Summary of AEs by participant across all dosing periods. N values represent the number of participants randomized to a sequence receiving one or more administrations of the treatment that were actually administered the treatment. In brackets, the percentage of participants experiencing adverse events with that treatment is given. Note that participants had twice as many opportunities to experience AEs on a particular treatment if they received the same treatment during two separate dosing periods.

ISSN: 1710-1492